Statistical alchemy for drug treatment of generalized anxiety disorder: A commentary on the meta-analysis by Baldwin et al. [BMJ 2011;342:d1199]

Psychotherapy and Psychosomatics

Volumn 80, Issue 5, 2011, Pages 261-263

  Fava, Giovanni A ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; FLUVOXAMINE; GABAPENTIN; LORAZEPAM; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BODY WEIGHT; CONFLICT OF INTEREST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FRAGILITY FRACTURE; GASTROINTESTINAL HEMORRHAGE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPONATREMIA; META ANALYSIS (TOPIC); OSTEOPOROSIS; OUTCOME ASSESSMENT; PANIC; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT RESPONSE;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; HUMANS; META-ANALYSIS AS TOPIC; PSYCHOTHERAPY;

EID: 79957941094     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000328768     Document Type: Review

References (23)

1. Feinstein AR: Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 1995; 48: 71-79.
2. Baldwin D, Woods R, Lawson R, Taylor D: Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011; 342:d1199.
3. Furukawa TA: Drug treatment for generalized anxiety disorder. BMJ 2011; 342:d1216.
4. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
5. Fava GA: The concept of recovery in affective disorders. Psychother Psychosom 1996; 65: 2-13. (Pubitemid 26041581)
6. Bech P: Fifty years with the Hamilton scales for anxiety and depression. Psychother Psychosom 2009; 78: 202-211.
7. Mitte K, Noack P, Steil R, Hautzinger M: A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 2005; 25: 141-150. (Pubitemid 40395092)
8. Berney P, Halperin D, Tango R, Daeniker-Dayer I, Schulz P: A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacol Bull 2008; 41: 39-47.
9. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Progr Neuropsychopharmacol Biol Psychiatry DOI: 10.1016/j.pnpbp.2010.07. 026.
10. Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835-838. (Pubitemid 350035823)
11. Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farré M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, van der Kreeft P, Scherbaum N: Is there a recreational misuse potential for pregabalin? Psychother Psychosom 2011; 80: 118-122.
12. Sensky T: The effectiveness of cognitive therapy for schizophrenia: what can we learn from the meta-analyses? Psychother Psychosom 2005; 74: 131-134.
13. Mitte K: Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull 2005; 131: 785-795. (Pubitemid 41463587)
14. Layard R: The case for psychological treatment centres. BMJ 2006; 332: 1030-1032. (Pubitemid 44365527)
15. Marks I: Mental health clinics in the 21st century. Psychother Psychosom 2009; 78: 133-138.
16. Rickels K, Etemad B, Khulid-Khan S, Lohoff FW, Rynn MA, Gallop RJ: Time to relapse after 6 and 12 months treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010; 67: 1274-1281.
17. Moret C, Isaac M, Briley M: Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacology 2009; 23: 967-974.
18. Fava GA, Porcelli P, Rafanelli C, Mangelli L, Grandi S: The spectrum of anxiety disorders in the medically ill. J Clin Psychiatry 2010; 71: 910-914.
19. Nieuwstraten C, Labiris NR, Holbrook A: Systematic overview of drug interactions with antidepressant medications. Can J Psychiatry 2006; 51: 300-316. (Pubitemid 43764713)
20. Dubovsky SL: Clinical Guide to Psychotropic Medications. New York, Norton, 2005.
21. Hindmarch I: Cognitive toxicity of pharmacotherapeutic agents in social anxiety disorder. Int J Clin Pract 2009; 63: 1085-1094.
22. Fux M, Taub M, Zohan J: Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993; 88: 235-237. (Pubitemid 23305177)
23. Fava GA: Unmasking special interest groups: the key to addressing conflict of interest in medicine. Psychother Psychosom 2010; 79: 203-207.